anlotinib – Medxy AI

Combining MEK inhibitor trametinib with pan-RTK inhibitor anlotinib shows high efficacy and manageable toxicity in treating advanced non-G12C KRAS-mutant NSCLC, overcoming adaptive resistance and offering improved clinical outcomes.

Low-Dose Morphine in COPD: Balancing Breathlessness Relief Against Sleep-Related Respiratory Risks
Dupilumab Enhances Quality of Life and Relieves Respiratory Symptoms in COPD Patients with Type 2 Inflammation: Insights from BOREAS and NOTUS Trials
Sustained Alterations in Glutamate Metabolism After Resistance Exercise in Older Adults With COPD and Healthy Controls
Innovative Airway Scaffolds Demonstrate Safety and Efficacy in Reducing Hyperinflation in Severe Emphysema: Six-Month BREATHE Trial Results
Targeting IL-33 in COPD: Insights from the Phase 2a FRONTIER-4 Trial of Tozorakimab

About us
Contact us
MedXY story
Privacy Policy
Subscribe Now!
账号

English
日本語
Tiếng Việt
中文

aging artificial intelligence blood pressure breast cancer béo phì cardiovascular health cardiovascular risk clinical trial COPD COVID-19 depression diabetes diet dinh dưỡng exercise GLP-1 health heart failure HFpEF Hypertension immunotherapy inflammation longevity mental health metformin Mortality nutrition obesity Pregnancy prevention public health randomized controlled trial randomized trial semaglutide sexual health Suy Tim sức khỏe tim mạch TAVI thử nghiệm lâm sàng tirzepatide type 2 diabetes weight loss wellness women's health 心力衰竭

Your health, we care

Scroll to Top